Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group)
| Autor: | C Scarabeli, C Guerra, Ignace Vergote, Petronella O. Witteveen, Corneel Coens, N. Reed, G Demonty, J. van der Velden |
|---|---|
| Přispěvatelé: | CCA -Cancer Center Amsterdam, Obstetrics and Gynaecology |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Paclitaxel Phases of clinical research Antineoplastic Agents Kaplan-Meier Estimate Neutropenia Disease-Free Survival medicine Humans Aged Vulvar Diseases Aged 80 and over Vulvar neoplasm integumentary system Vulvar Neoplasms urogenital system business.industry Standard treatment Cancer Original Articles Hematology Middle Aged Vulvar cancer medicine.disease female genital diseases and pregnancy complications Surgery Oncology Female Neoplasm Recurrence Local business Febrile neutropenia |
| Zdroj: | Annals of oncology, 20(9), 1511-1516. Oxford University Press |
| ISSN: | 0923-7534 |
| Popis: | Background: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. Patients and methods: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles. Primary objective was response rate. Secondary objectives were response duration and toxicity. Response evaluation was assessed by World Health Organisation criteria, toxicity according to Common Toxicity Criteria. Results: Thirty-one women from 10 institutions were included, with a median age of 64 (range 47–84), of which 29 were assessable for response. On study patients received a median of four cycles (range 1–10). Safety: Grade 3 and 4 neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and treatment-related death. Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and neuropathy in one patient (3.4%). Efficacy: Overall response was 13.8% (n = 4; two complete responses + two partial responses). With a median follow-up of 24 months, median PFS was 2.6 months (95%confidence interval 2.04–4.21). Conclusion: Paclitaxel shows moderate activity for local control in advanced vulvar cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|